Cortland Associates Inc. MO Sells 4,121 Shares of Becton, Dickinson and Company $BDX

Posted by Brian Himes on Nov 3rd, 2026

Cortland Associates Inc. MO cut its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 2.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 144,871 shares of the medical instruments supplier’s stock after selling 4,121 shares during the quarter. Becton, Dickinson and Company accounts for 3.8% of Cortland Associates Inc. MO’s portfolio, making the stock its 11th largest position. Cortland Associates Inc. MO’s holdings in Becton, Dickinson and Company were worth $25,932,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Maryland Capital Advisors Inc. lifted its holdings in Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares in the last quarter. Trifecta Capital Advisors LLC boosted its position in Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 62 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $198.77 on Tuesday. The firm has a fifty day moving average of $186.71 and a two-hundred day moving average of $170.25. The firm has a market cap of $54.77 billion, a P/E ratio of 15.01, a P/E/G ratio of 13.16 and a beta of 0.21. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the business posted $3.68 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on BDX shares. UBS Group assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Wolfe Research started coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada increased their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $185.07.

Get Our Latest Stock Analysis on Becton, Dickinson and Company

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,907 shares of company stock valued at $1,269,128 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.